Novartis CEO said he would unleash "one of the best and most-potent oncology sales and medical forces" to peddle copy-cat rituximab (the Novartis drug's generic name for Roche's Rituxan) in Europe as early as next year.

Rituxan sales hit $7.1 billion in 2015

Tidbit: Novartis owns one-third of Roche's voting stock, which it may unload